Patents Assigned to Macfarlane Burnet Institute for Medical Research and Public Health Limited
-
Publication number: 20230181726Abstract: A pharmaceutical composition comprising a nucleic acid molecule encoding a variable domain deleted E2 polypeptide of HCV (e.g., E2Delta123). The composition is suitable for use, for use, or when used, in the treatment or prevention of HCV infection. The nucleic acid molecule may be DNA or RNA or a modified or synthetic form, or contained within a plasmid, a viral or non-viral vector for vaccination, a polynucleotide expression cassette, or a cell for vector propagation. Methods of administration as prime and boost vaccinations are also provided.Type: ApplicationFiled: May 11, 2021Publication date: June 15, 2023Applicants: Macfarlane Burnet Institute for Medical Research and Public Health Limited, The Chancellor, Masters and Scholars of the University of OxfordInventors: Heidi DRUMMER, Eleanor Jane BARNES, Senthil Kumar CHINNAKANNAN
-
Patent number: 9598467Abstract: The invention provides modified hepatitis C virus (HCV) E2 glycoproteins comprising the HCV-E2 receptor-binding domain (RBD) including the HVR1, HVR2 and igVR variable regions wherein in at least one of said variable regions at least a part of the variable region is replaced with a flexible linker sequence. The invention also provides vaccine compositions comprising the modified glycoproteins as well as methods of use thereof.Type: GrantFiled: August 14, 2013Date of Patent: March 21, 2017Assignee: THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LIMITEDInventors: Kathleen McCaffrey, Heidi Drummer, Pantelis Poumbourios
-
Publication number: 20140120127Abstract: The invention provides modified hepatitis C virus (HCV) E2 glycoproteins comprising the HCV-E2 receptor-binding domain (RBD) including the HVR1, HVR2 and igVR variable regions wherein in at least one of said variable regions at least a part of the variable region is replaced with a flexible linker sequence. The invention also provides vaccine compositions comprising the modified glycoproteins as well as methods of use thereof.Type: ApplicationFiled: August 14, 2013Publication date: May 1, 2014Applicant: THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LIMITEDInventors: Kathleen McCaffrey, Heidi Drummer, Pantelis Poumbourios
-
Patent number: 8535686Abstract: The invention provides modified hepatitis C virus (HCV) E2 glycoproteins comprising the HCV-E2 receptor-binding domain (RBD) including the HVR1, HVR2 and igVR variable regions wherein in at least one of said variable regions at least a part of the variable region is replaced with a flexible linker sequence. The invention also provides vaccine compositions comprising the modified glycoproteins as well as methods of use thereof.Type: GrantFiled: August 24, 2007Date of Patent: September 17, 2013Assignee: The MacFarlane Burnet Institute for Medical Research and Public Health LimitedInventors: Kathleen McCaffrey, Heidi Drummer, Pantelis Poumbourios
-
Patent number: 8409818Abstract: The invention provides kits and methods for detecting or monitoring the number of cells in sample. The cell comprises a cell surface associated protein (CSAP) comprising a cytoplasmic (cytosolic) and an extracellular (ecto) domain. The kit comprises: (i) a chromatographic device; and (ii) a CSAP-binding agent. The method comprises: (i) optionally contacting the sample with an agent capable of lysing or permeabilizing CSAP bearing cells; (ii) contacting the sample with a CSAP-binding agent that binds to the cytoplasmic domain of the CSAP; and (iii) directly or indirectly evaluating the level or presence of bound CSAP in the sample.Type: GrantFiled: September 28, 2007Date of Patent: April 2, 2013Assignee: The Macfarlane Burnet Institute for Medical Research and Public Health LimitedInventors: David Andrew Anderson, Robyn Elizabeth Lloyd, Suzanne Mary Crowe, Mary Louise Garcia, Alan Lee Landay
-
Publication number: 20110244480Abstract: The invention provides kits and methods for detecting or monitoring the number of cells in sample. The cell comprises a cell surface associated protein (CSAP) comprising a cytoplasmic (cytosolic) and an extracellular (ecto) domain. The kit comprises: (i) a chromatographic device; and (ii) a CSAP-binding agent. The method comprises: (i) optionally contacting the sample with an agent capable of lysing or permeabilizing CSAP bearing cells; (ii) contacting the sample with a CSAP-binding agent that binds to the cytoplasmic domain of the CSAP; and (iii) directly or indirectly evaluating the level or presence of bound CSAP in the sample.Type: ApplicationFiled: September 28, 2007Publication date: October 6, 2011Applicant: The Macfarlane Burnet Institute for Medical Research and Public Health LimitedInventors: David Andrew Anderson, Robyn Elizabeth Lloyd, Suzanne Mary Crowe, Mary Louise Garcia, Alan Lee Landay
-
Publication number: 20100008951Abstract: The present invention relates to a vaccine composition comprising a carbohydrate polymer comprising mannose and flu antigen(s) (e.g. whole inactivated influenza virus) in admixture, and a method of immunising a subject comprising the step of administering the vaccine composition to a subject.Type: ApplicationFiled: October 2, 2007Publication date: January 14, 2010Applicant: THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LIMITEDInventors: Geoffrey Allan Pietersz, Sandra Elizabeth Esparon, Owen Proudfoot